
Two customer sites became the first MOSAIQ users to attest by proving meaningful use over a 90-day period
Users of Elekta’s MOSAIQ® Oncology Information System (OIS) – the first comprehensive, oncology-specific EMR certified for meaningful use under the federal government’s American Recovery and Reinvestment Act – have begun completing the “attestation” process to prove meaningful use. Fulfilling attestation requirements qualifies users of MOSAIQ and other systems to receive payments from the Centers for Medicare & Medicaid Services (CMS) of up to $44,000 over five years under Medicare rules.
Two Elekta customer sites became the first MOSAIQ users to attest in 2012 by proving meaningful use over a 90-day period. During that period, the centers were required to meet 20 patient-focused measures using MOSAIQ to record and manage patient records electronically.
Four medical oncologists at Cancer Specialists of Oklahoma (Oklahoma City, Okla.) submitted their attestations on April 5, qualifying each to receive $18,000 in incentive funds in 2012. Additional payments up to a total of $44,000 per physician are receivable until 2016 by continuing to meet meaningful use requirements under Medicare rules.
“Our physicians and staff are very pleased and proud at having met the challenging attestation requirements, and that they are in the first group of MOSAIQ users to do so,” says Margo Gonzales, Business Office Administrator at Cancer Specialists of Oklahoma.
A radiation oncologist from Tuality / Oregon Health & Science University (OHSU) Cancer Center LLC (Hillsboro, Ore.), submitted her attestation on April 12, according to Tina Dickerson, R.T.(R)(T), Chief Therapist/Manager at Tuality / OHSU Cancer Center, which is affiliated with the OHSU Knight Cancer Institute.
“Completing attestation for Stage 1 meaningful use is an accomplishment – I’m glad we were able to get it done this quickly,” she says. “The Elekta service group was on hand to help answer questions. The experience has made us more confident to achieve the next attestation for Stage 2 meaningful use.”